首页> Oncoimmunology> Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis.

Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ángela,Bella

第一单位： Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.;Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

作者： Ángela,Bella ^[1] ; Leire,Arrizabalaga ^[1] ; Claudia Augusta,Di Trani ^[1] ; Assunta,Cirella ^[1] ; Myriam,Fernandez-Sendin ^[1] ; Celia,Gomar ^[1] ; Joan Salvador,Russo-Cabrera ^[1] ; Inmaculada,Rodríguez ^[1] ; José,González-Gomariz ^[1] ; Maite,Alvarez ^[2] ; Álvaro,Teijeira ^[2] ; José,Medina-Echeverz ^[3] ; Maria,Hinterberger ^[3] ; Hubertus,Hochrein ^[3] ; Ignacio,Melero ^[4] ; Pedro,Berraondo ^[2] ; Fernando,Aranda ^[1]

作者单位： Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.;Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. ^[1] Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.;Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.;Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. ^[2] Immunology Research, Bavarian Nordic GmbH, Planegg, Germany. ^[3] Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.;Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.;Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.;Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.;Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain. ^[4]

关键词 CD137L CD40L CD8 immune response Peritoneal carcinomatosis cancer immunotherapy